Should Shareholders Be Beneficent—Or Benevolent?
Business and Professional Ethics Journal · 2026 · 45 (2) · 211-255
DOI: 10.5840/bpej2026616189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Business and Professional Ethics Journal, 2026. Verfasst von Kevin T. Jackson. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
This paper advances a virtue-theoretic reinterpretation of shareholder moral responsibility, proposing a shift from beneficence—an action-based duty to do good—toward benevolence, understood as a stable virtue of character. Engaging Santiago Mejia’s deontological account of shareholder discretion and latitude in discharging imperfect duties, it argues that such action-based models, while structurally clarifying, leave unexamined the moral quality of the agent herself. Drawing on Aristotelian concepts of phronēsis, aisthesis, and hexis, the paper contends that shareholders are genuine moral agents whose investment, voting, and engagement decisions shape and are shaped by their character. It introduces the notion of “vicious beneficence”—praiseworthy acts undertaken from vice, as in strategic philanthropy—to show why disposition, not merely outcome, matters morally. Rather than displacing deontology, the argument integrates the two frameworks: duty supplies structure, virtue supplies motivation and perception. Benevolence thus emerges as a foundational business virtue grounding capitalism’s moral legitimacy.
Zitieren
APA
Jackson, K. T. (2026). Should Shareholders Be Beneficent—Or Benevolent?. Business and Professional Ethics Journal, 45(2), 211-255. https://doi.org/10.5840/bpej2026616189
Vancouver
Jackson KT. Should Shareholders Be Beneficent—Or Benevolent?. Business and Professional Ethics Journal. 2026;45(2):211-255. doi:10.5840/bpej2026616189
BibTeX
@article{Jackson2026,
author = {Jackson, Kevin T.},
title = {Should Shareholders Be Beneficent—Or Benevolent?},
journal = {Business and Professional Ethics Journal},
year = {2026},
volume = {45},
number = {2},
pages = {211--255},
doi = {10.5840/bpej2026616189}
}
EUVIMED